Free Trial
Edward Tenthoff

Edward Tenthoff Analyst Performance

Sr Research Analyst at Piper Sandler

Edward Tenthoff is a stock analyst at Piper Sandler focused in the medical sector, covering 57 publicly traded companies. Over the past year, Edward Tenthoff has issued 14 stock ratings, including and buy recommendations. While full access to Edward Tenthoff's proprietary MarketBeat Analyst Ranking is reserved for MarketBeat All Access subscribers, the rating is updated daily to reflect the most recent analyst activity. This profile highlights Edward Tenthoff's coverage history, rating activity, and performance tendencies — helping individual investors make more informed trading decisions.

Analyst Rankings, Coverage, and Performance Statistics

Average Return
00.00% 12-Month ROI
Success Rate
00.00% Profitable Ratings
Total Ratings
238 Last 10 Years
Buy Recommendations
80.00% 180 Buy Ratings
Companies Covered
57 Unique Companies

Ratings Distribution

RatingPercentageCount
Strong Buy0.0%0 ratings
Buy80.0%180 ratings
Hold18.2%41 ratings
Sell1.8%4 ratings

Out of 225 total stock ratings issued by Edward Tenthoff at Piper Sandler, the majority (80.0%) have been Buy recommendations, followed by 18.2% Hold and 1.8% Sell.

Exchange Coverage

ExchangePercentageCount
NASDAQ
93.0% of companies on NASDAQ
53 companies
OTCMKTS
3.5% of companies on OTCMKTS
2 companies
NYSEAMERICAN
1.8% of companies on NYSEAMERICAN
1 company
NYSE
1.8% of companies on NYSE
1 company

Edward Tenthoff, an analyst at Piper Sandler, currently covers 57 companies listed on NASDAQ, OTCMKTS, NYSEAMERICAN and NYSE, with the majority traded on NASDAQ.

Coverage Focus

Sector IconSectorPercentage
Medical
53 companies
93.0%
Miscellaneous
2 companies
3.5%
Energy
1 company
1.8%
Transportation
1 company
1.8%

Edward Tenthoff of Piper Sandler specializes in stock coverage within the Medical sector, with additional focus on and Energy companies.

Coverage Industries

IndustryPercentage
MED - BIOMED/GENE
27 companies
47.4%
PHARMACEUTICAL PREPARATIONS
13 companies
22.8%
BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC
5 companies
8.8%
MED - DRUGS
4 companies
7.0%
Miscellaneous
2 companies
3.5%
BIOTECHNOLOGY
2 companies
3.5%
MED PRODUCTS
1 company
1.8%
MED INSTRUMENTS
1 company
1.8%
SOLAR
1 company
1.8%
TRANS - AIRLINE
1 company
1.8%

Edward Tenthoff's Ratings History at Piper Sandler

Recommendation ROI is the percentage between the price on the Report Date to the price 12 months after the report date.
Available with a MarketBeat All Access Subscription
12-Month ROIUpgrade to All Access to use the All ROI Filter
CompanyReport DateActionReport Date Price12-Month
Price Target
Rating12-Month
Price & ROI
Details
Karyopharm Therapeutics Inc. stock logo
KPTI
Karyopharm Therapeutics
10/9/2025Reiterated Rating$5.75$12.00Overweight
CAMP4 Therapeutics Corporation stock logo
CAMP
CAMP4 Therapeutics
9/15/2025Lower Price Target$3.25$12.00Overweight
Alnylam Pharmaceuticals, Inc. stock logo
ALNY
Alnylam Pharmaceuticals
8/1/2025Boost Price Target$392.24$449.00Overweight
NextCure, Inc. stock logo
NXTC
NextCure
7/15/2025Set Price Target$4.85$15.00Overweight
Capricor Therapeutics, Inc. stock logo
CAPR
Capricor Therapeutics
7/11/2025Reiterated Rating$7.94$20.00Overweight
Inovio Pharmaceuticals, Inc. stock logo
INO
Inovio Pharmaceuticals
7/9/2025Initiated Coverage$1.34$5.00Overweight
CRISPR Therapeutics AG stock logo
CRSP
CRISPR Therapeutics
6/27/2025Reiterated Rating$47.45$105.00Overweight
Biomea Fusion, Inc. stock logo
BMEA
Biomea Fusion
6/3/2025Initiated Coverage$1.55$7.00Overweight
Fulcrum Therapeutics, Inc. stock logo
FULC
Fulcrum Therapeutics
5/29/2025Reiterated Rating$6.90$9.00Overweight
iTeos Therapeutics, Inc. stock logo
ITOS
iTeos Therapeutics
5/14/2025Reiterated Rating$7.33$12.00Overweight
Arvinas, Inc. stock logo
ARVN
Arvinas
5/2/2025Reiterated Rating$7.02$14.00Overweight
Century Therapeutics, Inc. stock logo
IPSC
Century Therapeutics
3/20/2025Lower Price Target$0.54$2.00Overweight
Dyne Therapeutics, Inc. stock logo
DYN
Dyne Therapeutics
2/28/2025Lower Price Target$13.17$48.00Overweight
Mesoblast Limited stock logo
MESO
Mesoblast
2/7/2025Reiterated Rating$19.85$24.00Overweight